Department of Emergency Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Shock. 2024 Nov 1;62(5):716-727. doi: 10.1097/SHK.0000000000002453. Epub 2024 Aug 23.
Hemorrhagic shock (HS) is a life-threatening condition with high mortality rates despite current treatments. This study investigated whether targeted temperature management (TTM) could improve outcomes by modulating inflammation and protecting organs following HS. Using a rat model of HS, TTM was applied at 33°C and 36°C after fluid resuscitation. Surprisingly, TTM at 33°C increased mortality, while TTM at 36°C significantly improved survival rates. It also reduced histological damage in lung and kidney tissues, lowered serum lactate levels, and protected against apoptosis and excessive reactive oxygen species production. TTM at 36°C inhibited the release of high mobility group box 1 protein (HMGB1), a key mediator of inflammation, and decreased proinflammatory cytokine levels in the kidneys and lungs. Moreover, it influenced macrophage behavior, suppressing the harmful M1 phenotype while promoting the beneficial M2 polarization. Cytokine array analysis confirmed reduced levels of proinflammatory cytokines with TTM at 36°C. These results collectively highlight the potential of TTM at 36°C as a therapeutic approach to improve outcomes in HS. By addressing multiple aspects of injury and inflammation, including modulation of macrophage responses and cytokine profiles, TTM at 36°C offers promising implications for critical care management after HS, potentially reducing mortality and improving patient recovery.
失血性休克(HS)是一种危及生命的病症,尽管目前有治疗方法,但死亡率仍然很高。本研究旨在探讨靶向体温管理(TTM)是否可以通过调节炎症和保护 HS 后器官来改善预后。使用 HS 大鼠模型,在液体复苏后将 TTM 应用于 33°C 和 36°C。令人惊讶的是,33°C 的 TTM 增加了死亡率,而 36°C 的 TTM 显著提高了生存率。它还减少了肺和肾组织的组织学损伤,降低了血清乳酸水平,并防止了细胞凋亡和过多的活性氧产生。36°C 的 TTM 抑制了高迁移率族蛋白 B1(HMGB1)的释放,HMGB1 是炎症的关键介质,并降低了肾脏和肺部的促炎细胞因子水平。此外,它还影响了巨噬细胞的行为,抑制了有害的 M1 表型,同时促进了有益的 M2 极化。细胞因子阵列分析证实,36°C 的 TTM 降低了促炎细胞因子的水平。这些结果共同强调了 36°C 的 TTM 作为改善 HS 预后的治疗方法的潜力。通过调节巨噬细胞反应和细胞因子谱等多个损伤和炎症方面,36°C 的 TTM 为 HS 后重症监护管理提供了有希望的应用前景,可能降低死亡率并改善患者的康复。